Adult Phase 3 study results for serum phosphorus,
XLH-associated stiffness, and fractures
Learn more about the CRYSVITA safety profile
CRYSVITA dosing and administration recommendations and dosing calculator
Understand how CRYSVITA
works
XLH IN ADULT PATIENTS
- XLH is the most common cause of inherited phosphorus wasting and leads to poor bone mineralization.1-3
- Consequentially, adults who have been living with XLH can be impacted by osteomalacia, pseudofractures and fractures, XLH-associated stiffness, and a reduced quality of life.1,2
Data for CRYSVITA on serum phosphate levels, XLH-associated stiffness, osteomalacia-related fractures, and pseudofractures in adults with XLH are presented elsewhere in this piece. CRYSVITA’s effects on quality of life have not been evaluated as predefined endpoints in clinical trials.
References: 1. Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455.
2. Dahir K, et al. X-linked hypophosphatemia: A new era in management. J Endocr Soc. 2020;4(12):bvaa151. 3. Glorieux FH, et al. Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet J Rare Dis. 2022;17(1):30.
